

28th July, 2023

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex, Bandra
(East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ('Listing Regulations')

Dear Sir / Madam,

Pursuant to Regulation 30(6) of the Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.

Kind take this on record.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com

Q1 FY24 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **4th August 2023 at 4:00 PM (IST) to discuss its Q1FY24 Results.**

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 4 th August, 2023	India – 4:00 PM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 6:30 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 11:30 AM (London Time)	Toll free number 08081011573
	Singapore – 6:30 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 6:30 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9503078&linkSecurityString=33aa158d84	

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, PPL received 20% strategic growth investment from the Carlyle Group.

For more information visit: <https://www.piramal.com/pharma/>, [Facebook](#), [Twitter](#), [LinkedIn](#)

For Media Queries:

Rajiv Banerjee
Group Head - Corporate Communications
rajiv.banerjee@piramal.com

For Investors:

Gagan Borana
General Manager - Investor Relations & Sustainability
gagan.borana@piramal.com

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com